Navigation Links
Japanese Cancer Association and Debiopharm Honour Japanese Research
Date:10/29/2008

Professors Ichijo and Mano Receive 2008 JCA-Mauvernay Award

LAUSANNE, Switzerland, October 29 /PRNewswire/ -- Debiopharm Group (Debiopharm), a global biopharmaceutical development specialist that focuses on serious medical conditions and particularly oncology, presented Professors Hidenori Ichijo and Hiroyuki Mano with the 2008 JCA-Mauvernay Award for their outstanding basic and applied research work in oncology. The Awards were presented during the General Assembly of the 67th Annual Conference of the Japanese Cancer Association (JCA) in Japan, by Professor Setsuo Hirohashi, President of the JCA and Dr Rolland-Yves Mauvernay, Founder and President of Debiopharm Group.

The basic research of Professor Ichijo, from the Graduate School of Pharmaceutical Sciences at the University of Tokyo, focuses on "Stress Signalling and Cancer" and more specifically on the discovery of a protein tyrosine kinase called the apoptosis signal-regulating kinase 1 (ASK1). ASK1 controls cellular responses to stress and therefore plays a key role in cancer, innate immunity and wound-induced inflammation.

The research work conducted by Professor Mano, from the Functional Genomics Division at Jichi Medical University, focuses on "Discovery of a novel fusion oncogene, EML4-ALK present in lung cancer and its clinical implications". EML4-ALK (echinoderm microtubule associated protein like 4 - anaplastic lymphoma kinase) is a fusion protein resulting from a chromosomal translocation present in a relatively large percentage of NSCLCs (non-small cell lung cancers), a disease in which cancer cells form in the tissues of the lung. This novel onco-gene is a potential target for cancer therapy and biomarker development.

"Significant steps in the understanding of major aspects of oncogenesis were rewarded with this Award. The work of Professors Ichijo and Mano will help the scientific community to better understand the mechanisms involved in cancer, immunity and inflammation, as we strive to bring sufferers more targeted and effective drugs in the near future," said Kamel Besseghir, CEO of Debiopharm S.A.

In its fourth year, the JCA-Mauvernay Award is organised jointly by the JCA and Debiopharm to honour innovative fundamental and clinical oncology research and to encourage Japanese scientists to make their work available outside Japan.

This year Debiopharm has already presented two Awards in Switzerland: in August, the "Debiopharm Life Sciences Award" designed to mentor and motivate young innovative European researchers in the field of life sciences, and in June, the "Prix Debiopharm Valais pour les Sciences de la Vie" aimed at encouraging entrepreneurship in the life sciences and technology sectors in the canton of Valais.

About Debiopharm Group

Debiopharm Group is a global biopharmaceutical development specialist that in-licenses promising biologics and small molecule drug candidates. It develops its products for global registration and maximum commercial potential for out-licensing to pharmaceutical partners for sales and marketing.

Debiopharm independently funds the worldwide development of all of its products while providing expertise in pre-clinical and clinical trials, manufacturing, drug delivery and formulation, and regulatory affairs.

Founded in 1979 and headquartered in Lausanne, Switzerland, Debiopharm has developed three products with global combined sales in excess of $2.65 billion in 2007.

For more information on Debiopharm Group, please visit: http://www.debiopharm.com.

Debiopharm S.A. Contacts

Maurice Wagner

Director Corporate Affairs & Communications

Tel.: +41(0)21-321-01-11

Fax: +41(0)21-321-01-69

mwagner@debiopharm.com

Jo-Anne Lutjens

Communications Manager

Tel.: +41(0)79-370-27-15

Fax: +41(0)21-321-01-69

jalutjens@debiopharm.com

Additional Media Contacts

In London

Maitland

Brian Hudspith

Tel: +44(0)20-7379-5151

bhudspith@maitland.co.uk

In New York

Russo Partners, LLC

Wendy Lau

Tel: +1-212-845-4272

Fax: +1-212-845-4260

wendy.lau@russopartnersllc.com


'/>"/>
SOURCE Debiopharm Group
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. InterMune Reports Japanese Regulatory Approval of Pirfenidone in IPF
2. Circassia Acquires North American and Japanese Rights to Dopexamine
3. Biopten (Sapropterin Dihydrochloride) Approved by Japanese Ministry of Health for the Treatment of PKU
4. Aortic Stent Grafts Will Boost Canadian and Japanese Peripheral Vascular Markets
5. Boston Scientific Announces Japanese Approval of Heart Failure Lead
6. Naglazyme Approved by Japanese Ministry of Health
7. Corgenix Signs Technology Licensing Agreement With Japanese Government
8. Pharsight Welcomes Newest Japanese PKS, AutoPilot Customer
9. Japanese Cancer Association and Debiopharm Honour Professors Minoru Toyota and Keiichi Nakayama With the 2007 JCA-Mauvernay Award
10. Diagenic Partners With DNAVision to Offer First Breast Cancer and Alzheimers Gene-Expression Blood Tests
11. Sirnaomics Receives SBIR Grant from NCI For Its Multi-Targeted Cancer siRNA Therapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2017)... ... September 19, 2017 , ... Avomeen ... the recipients of its 2017 Science Student Award. The scholarship program is dedicated ... with community service defray the costs of obtaining their science education. , Avomeen ...
(Date:9/19/2017)... Austin, TX (PRWEB) , ... ... ... New York State Department of Financial Services (NYS DFS) cybersecurity ... all regulated banking, finance and insurance organizations operating in the state (“Covered ...
(Date:9/18/2017)... ... September 18, 2017 , ... Transportable biomass ... briquettes, and torrefied wood is the topic of a September 27 webinar ... potential economic viability of transportable biomass conversion facilities for producing biochar, briquettes, and ...
(Date:9/18/2017)... MONTREAL , Sept. 18, 2017   Montrium , a ... announced an exciting new partnership with a groundbreaking non-profit research organization, ... ... for MDMA-assisted psychotherapy studies for PTSD ... FDA has recently granted Breakthrough Therapy Designation to MDMA for the ...
Breaking Biology Technology:
(Date:6/14/2017)... -- IBM (NYSE: IBM ) is introducing several innovative partner ... developing collaboration between startups and global businesses, taking place in ... event, nine startups will showcase the solutions they have built ... France is one of ... 30 percent increase in the number of startups created between ...
(Date:5/16/2017)...   Bridge Patient Portal , an enterprise ... EMR Systems , an electronic medical record solutions ... established a partnership to build an interface between ... Centricity™ products, including Centricity Practice Solution (CPS), Centricity ... new integrations will allow healthcare delivery networks using ...
(Date:4/19/2017)... York , April 19, 2017 ... as its vendor landscape is marked by the presence ... market is however held by five major players - ... Together these companies accounted for nearly 61% of the ... the leading companies in the global military biometrics market ...
Breaking Biology News(10 mins):